{"nctId":"NCT00965757","briefTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate","startDateStruct":{"date":"2009-07-31","type":"ACTUAL"},"conditions":["Rheumatoid Arthritis"],"count":253,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: T-614"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"T-614","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Subjects who have a diagnosis of Rheumatoid Arthritis by the ACR criteria\n* Age greater or 20 years and less than 70 years old\n\nExclusion criteria:\n\n* Subject who is considered by the investigator, for any reason, to be an unsuitable candidate for the study\n* Women of childbearing potential who are not practicing a successful method of contraception, or wish to become pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"69 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline in Tender Joint Counts and Swollen Joint Counts","description":"Assessment of individual ACR core components like Tender Joint Counts (TJC) and Swollen Joint Counts (SJC)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":"6.5"},{"groupId":"OG001","value":"13.3","spread":"8.1"},{"groupId":"OG002","value":"13.8","spread":"8.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"6"},{"groupId":"OG001","value":"-4.6","spread":"7.8"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"6.1"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-9.9","spread":"7.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":"6.3"},{"groupId":"OG001","value":"11.1","spread":"5.7"},{"groupId":"OG002","value":"10.9","spread":"5.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"5.9"},{"groupId":"OG001","value":"-2.9","spread":"6.7"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"6.8"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-6.3","spread":"6.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PAP, PtGADA and PyGADA","description":"Patient's assessment of pain (PAP), patient's global assessment of disease activity (PtGADA) and physician's global assessment of disease activity (PyGADA) each was assessed on a visual analog scale ranging from 0-100 mm, with higher scores indicating severe disease.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":"22.2"},{"groupId":"OG001","value":"46.4","spread":"23.1"},{"groupId":"OG002","value":"44.8","spread":"22.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22","spread":"23.8"},{"groupId":"OG001","value":"-2.5","spread":"27"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24","spread":"24.1"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-21.4","spread":"26.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":"24.3"},{"groupId":"OG001","value":"50.1","spread":"23.5"},{"groupId":"OG002","value":"48.4","spread":"23.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.2","spread":"26.4"},{"groupId":"OG001","value":"-5","spread":"27.1"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.3","spread":"26"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-23.1","spread":"27.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","spread":"18.3"},{"groupId":"OG001","value":"53.2","spread":"19"},{"groupId":"OG002","value":"52.1","spread":"17.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.1","spread":"19.3"},{"groupId":"OG001","value":"-10.4","spread":"26.6"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.1","spread":"22.4"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-29.9","spread":"24.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)","description":"HAQ-DI was a participant assessed measure of health assessment, measured on a single scale ranging from 0 (no difficulty) to 3 (unable to do), with higher scores indicating severe disease.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8178","spread":"0.5525"},{"groupId":"OG001","value":"0.7344","spread":"0.5117"},{"groupId":"OG002","value":"0.7188","spread":"0.5274"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3544","spread":"0.4492"},{"groupId":"OG001","value":"0.0256","spread":"0.549"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4093","spread":"0.4566"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-0.2904","spread":"0.4669"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in C-reactive Protein (CRP)","description":"Assessment of individual ACR core components i.e. CRP","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.843","spread":"1.943"},{"groupId":"OG001","value":"1.705","spread":"1.583"},{"groupId":"OG002","value":"1.714","spread":"1.611"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.528","spread":"2.067"},{"groupId":"OG001","value":"0.47","spread":"2.028"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.609","spread":"1.841"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-0.581","spread":"1.866"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Erythrocyte Sedimentation Rate (ESR)","description":"Assessment of individual ACR core components i.e. ESR","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":"21"},{"groupId":"OG001","value":"41.8","spread":"22.5"},{"groupId":"OG002","value":"40.1","spread":"23.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.3","spread":"20.8"},{"groupId":"OG001","value":"2.6","spread":"19.7"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.4","spread":"21.3"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"-8.8","spread":"21.5"}]}]}]},{"type":"SECONDARY","title":"Disease Activity Score in 28 Joints (DAS28): The Rates of Remission (DAS28-CRP Less Than 2.6), and Low Disease Activity (DAS28-CRP Less Than 3.2)","description":"The DAS28 is a composite score derived from 4 of these measures i.e count of 28 swollen joints, 28 tender joints, measure erythrocyte sedimentation rate (ESR) or C reactive protein (CRP) and to make a 'global assessment of health' (indicated by marking a 10 cm line between very good and very bad). DAS28 is assessed as score on scale from 0 to 10 indicating current rheumatoid arthritis (RA) disease activity (0= low disease activity and 10 = high disease activity).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of ACR 50 Criteria Responders","description":"ACR50 response is defined as at least a 50% improvement in tender joint count and swollen joint count, and in three of five of the following measures: patient pain intensity assessment, patient global assessment, physician global assessment, Health assessment questionnaire disability index (HAQ-DI), and an acute phase reactant \\[erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)\\].","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","spread":null},{"groupId":"OG001","value":"15.9","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.4","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"45.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of ACR 70 Criteria Responders","description":"ACR70 response is defined as at least a 70% improvement in tender joint count and swollen joint count, and in three of five of the following measures: patient pain intensity assessment, patient global assessment, physician global assessment, Health assessment questionnaire disability index (HAQ-DI), and an acute phase reactant \\[erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)\\].","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null},{"groupId":"OG001","value":"5.7","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"22.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of American College of Rheumatology [ACR] 20 Criteria Responders","description":"ACR20 response is defined as at least a 20% improvement in tender joint count and swollen joint count, and in three of five of the following measures: patient pain intensity assessment, patient global assessment, physician global assessment, Health assessment questionnaire disability index (HAQ-DI), and an acute phase reactant \\[erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)\\].","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","spread":null},{"groupId":"OG001","value":"30.7","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"72.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":164},"commonTop":["Nasopharyngitis","Blood iron decreased","Lymphocyte count decreased","Alanine aminotransferase increased","Aspartate aminotransferase increased"]}}}